- Home
- Publications
- Publication Search
- Publication Details
Title
Evolution of a New Class of Antihypertensive Drugs
Authors
Keywords
-
Journal
HYPERTENSION
Volume 75, Issue 1, Pages 6-15
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-12-02
DOI
10.1161/hypertensionaha.119.12675
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension
- (2019) Michel Azizi et al. JOURNAL OF HYPERTENSION
- Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins
- (2019) Keith C. Ferdinand et al. CIRCULATION
- NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension
- (2019) Mathilde Keck et al. HYPERTENSION
- Emerging Drug Classes and Their Potential Use in Hypertension
- (2019) Michel Azizi et al. HYPERTENSION
- Central antihypertensive effects of chronic treatment with RB150
- (2018) Yannick Marc et al. JOURNAL OF HYPERTENSION
- The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7)
- (2018) Robson Augusto Souza Santos et al. PHYSIOLOGICAL REVIEWS
- Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
- (2018) Robert M. Carey et al. HYPERTENSION
- Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Mohammad H Forouzanfar et al. LANCET
- A new strategy for treating hypertension by blocking the activity of the brain renin–angiotensin system with aminopeptidase A inhibitors
- (2014) Ji Gao et al. CLINICAL SCIENCE
- Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
- (2013) Fabrice Balavoine et al. CLINICAL PHARMACOKINETICS
- Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction
- (2012) Bing S. Huang et al. CARDIOVASCULAR RESEARCH
- Central Antihypertensive Effects of Orally Active Aminopeptidase A Inhibitors in Spontaneously Hypertensive Rats
- (2012) Yannick Marc et al. HYPERTENSION
- Initial Combination Therapy Reduces the Risk of Cardiovascular Events in Hypertensive Patients
- (2012) Alan H. Gradman et al. HYPERTENSION
- Therapy of Hypertension in African Americans
- (2011) John M. Flack et al. American Journal of Cardiovascular Drugs
- Management of High Blood Pressure in Blacks
- (2010) John M. Flack et al. HYPERTENSION
- Drug Therapy for Resistant Hypertension: Simplifying the Approach
- (2010) Samuel J. Mann Journal of Clinical Hypertension
- The Hypertension Paradox — More Uncontrolled Disease despite Improved Therapy
- (2009) Aram V. Chobanian NEW ENGLAND JOURNAL OF MEDICINE
- Orally Active Aminopeptidase A Inhibitors Reduce Blood Pressure
- (2008) Laurence Bodineau et al. HYPERTENSION
- Global burden of obesity in 2005 and projections to 2030
- (2008) T Kelly et al. INTERNATIONAL JOURNAL OF OBESITY
- Human brain aminopeptidase A: biochemical properties and distribution in brain nuclei
- (2008) Nadia de Mota et al. JOURNAL OF NEUROCHEMISTRY
- Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
- (2008) Kenneth Jamerson et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started